About NSCLC Immunotherapy: Advancing Hope™
Launched in July of 2016, SITC presents the newest in a series of videos focusing on immunotherapy for NSCLC patients, the NSCLC Immunotherapy: Advancing HopeTM video provides an overview of the building blocks of the immune system and immunotherapy, while also highlighting some* of the available FDA approved immunotherapy treatments and potential side effects, and the importance of clinical trials. Through a highly informative and easy-to-understand whiteboard animated format, follow an advanced NSCLC patient who is introduced to immunotherapy and is looking to determine if it is the right treatment option for him.
Patients! Watch this video to learn more about immunotherapy for NSCLC and start the conversation with your doctor to find out if it is a good treatment option for you.
More Patient and Clinician Resources: Visit SITC's new website, Cancer Immunotherapy CONNECT, the source and resource for all things cancer immunotherapy related.
SITC is pleased to offer a CME- and CNE-certified online activity for physicians and registered nurses to complete. Presented through detailed written case studies, this activity is designed to provide physicians and registered nurses with a more in-depth overview of what they will need to know when considering and utilizing immunotherapy with NSCLC patients in the clinical setting.
Inclusive of this activity is a "Frequently Asked Question" takeaway for physicians and registered nurses, which reiterates important pieces of information learned in the activity in language soluble enough to impart on patients.
Physicians and Registered Nurses! Complete this activity to learn more targeted information on immunotherapy for NSCLC and claim your CE credits today!
*This video and activity were produced prior to the October 2016 FDA approvals of 1) TECENTRIQ® (atezolizumab, Genentech, Inc.) in patients whose disease progressed despite treatment with platinum-containing chemotherapy and 2) KEYTRUDA® (pembrolizumab; Merck & Co., Inc.) as first-line therapy in patients whose tumors express high levels of PD-L1 on an FDA-approved test, without certain genetic mutations (EGFR or ALK). As a leader in the field of cancer immunotherapy research and education, SITC will continue to update it's educational programming in immunotherapy as treatments become available.
This initiative was produced in collaboration with:
Funding for this project was generously provided by AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, and Merck & Co., Inc.
About the Video
Launch in May of 2014, the Society for Immunotherapy of Cancer (SITC) created, Non-small Cell Lung Cancer Immunotherapy: A New Hope™ is an animated video that follows a patient’s journey from her diagnosis of NSCLC through the process of learning about cancer immunology, leading to her consideration of cancer immunotherapy treatments via clinical trial participation.
This video was produced prior to the 2015 US FDA approvals of Opdivo® (nivolumab) for the treatment of squamous and non-squamous non-small cell lung cancer and Keytruda® (pembrolizumab) for the treatment of non-small cell lung cancer in patients whose tumors express PD-L1. More educational resources will be developed in this area as advancements in the field continue.
This video was produced in collaboration with:
Funding for this project was generously provided by Bristol-Myers Squibb.
The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient. This information is intended only for residents of the United States.